Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection.
Katharina SinnBerta MoslehMichael GruschWalter KlepetkoKonrad HoetzeneckerThomas KlikovitsDaniela GompelmannMir Alireza HodaPublished in: BMC cancer (2022)
Elevated fibrinogen levels after neoadjuvant therapy prior to surgery in stage III/N2 NSCLC patients are associated with significant disadvantage for OS. A decrease in fibrinogen levels after neoadjuvant therapy was found to be a predictor for superior OS in this retrospective patient cohort.
Keyphrases
- rectal cancer
- lymph node
- locally advanced
- end stage renal disease
- small cell lung cancer
- minimally invasive
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- ejection fraction
- stem cells
- radiation therapy
- prognostic factors
- cross sectional
- mesenchymal stem cells
- coronary artery bypass
- epidermal growth factor receptor